Managing Psychiatric Adverse Effects of Levetiracetam
If a patient on levetiracetam develops mood instability, immediately assess severity: for mild-to-moderate symptoms, reduce the levetiracetam dose by 25-50%; for severe symptoms including aggression, psychosis, or suicidality, discontinue levetiracetam immediately and switch to an alternative antiepileptic drug such as lacosamide or brivaracetam.
Understanding the Psychiatric Risk Profile
Levetiracetam carries a well-documented risk of psychiatric and behavioral adverse effects. According to FDA labeling, non-psychotic behavioral disorders (aggression, irritability) occur in 5-11.4% of patients, and non-psychotic mood disorders (depression, mood swings) occur in 6.7-12.7% of patients 1. These rates substantially exceed placebo (0-3.6%). Approximately 3-5% of patients require dose reduction or discontinuation due to these psychiatric events 1.
The psychiatric adverse effects include:
- Common: Irritability, aggression, anxiety, depression, mood swings, hostility
- Serious but less common: Psychosis with hallucinations, suicidal ideation, severe rage episodes 1
Risk Stratification Before and During Treatment
High-Risk Patients Requiring Enhanced Monitoring:
- Prior psychiatric history (mood disorders, psychosis, behavioral problems)
- Male sex
- Age <60 years
- Poorly controlled epilepsy
- Pediatric patients (12-38.7% incidence of behavioral effects) 2
Critical monitoring window: Most psychiatric adverse effects emerge within the first 4 weeks of initiation or dose escalation, though onset can occur up to 90 days later 1, 3. The mean time to onset is approximately 30 days 3.
Algorithmic Management Approach
Step 1: Severity Assessment
Mild symptoms (irritability, mild anxiety, mood changes without functional impairment):
- Reduce levetiracetam dose by 25-50%
- Monitor closely for 2-4 weeks
- Symptoms typically resolve within 3-4 months of dose adjustment 3
Moderate symptoms (significant aggression, marked depression, behavioral dysregulation affecting function):
- Reduce dose by 50% OR discontinue entirely
- Consider adjunctive psychiatric medication if needed during transition
- Switch to alternative AED (see below)
Severe symptoms (psychosis, suicidal ideation/behavior, uncontrollable rage, violence):
- Discontinue levetiracetam immediately 4, 5
- Initiate psychiatric crisis management
- May require temporary antipsychotic medication for acute symptom control 2
- Switch to alternative AED urgently
Step 2: Alternative Antiepileptic Selection
When switching from levetiracetam due to psychiatric adverse effects:
First-line alternatives:
- Lacosamide: Preferred switch in recent case reports, good psychiatric tolerability 4, 3
- Sodium valproate: Established alternative with mood-stabilizing properties 3
- Brivaracetam: Higher SV2A selectivity, generally better psychiatric profile than levetiracetam, though caution in bipolar disorder 6, 2
Note on brivaracetam: While it has improved psychiatric tolerability compared to levetiracetam, a 2026 case report documents a manic episode in a patient with bipolar disorder 6. Exercise caution in patients with mood disorders.
Step 3: Psychiatric Co-Management
For patients requiring continued treatment during symptom resolution:
- Coordinate with psychiatry for severe cases
- Consider temporary anxiolytics for anxiety symptoms
- Antipsychotics may be needed for psychotic symptoms
- Mood stabilizers for bipolar-like presentations
- Close monitoring for suicidality (FDA black box warning applies to all AEDs) 1
Critical Clinical Pitfalls
Dose-dependent effects: The FDA label shows discontinuation rates increase dramatically with higher doses (3% at placebo, 67% at 2,400 mg/day for oxcarbazepine as reference) 7. Start low, titrate slowly.
Rechallenge risk: Multiple case reports document immediate recurrence of psychiatric symptoms upon levetiracetam reintroduction 5. Do not rechallenge patients who experienced severe psychiatric adverse effects.
Pediatric vulnerability: Children show higher rates of behavioral problems (37.6% vs 18.6% placebo), with hostility in 11.9% and nervousness in 9.9% 1. Lower threshold for intervention in pediatric patients.
Withdrawal seizures: When discontinuing levetiracetam, taper gradually to minimize seizure risk 1. However, in psychiatric emergencies, seizure risk from abrupt discontinuation may be acceptable compared to psychiatric harm.
Delayed onset: Symptoms can emerge weeks after stable dosing 3. Maintain vigilance beyond initial titration period.
Monitoring Protocol
- Baseline: Screen for psychiatric history before initiating levetiracetam
- Weeks 1-4: Weekly assessment for behavioral changes (highest risk period)
- Months 2-3: Biweekly monitoring
- Ongoing: Educate patients/caregivers to report mood changes, aggression, or suicidal thoughts immediately 1
The resolution timeline after intervention is typically 3-4 months for complete symptom resolution 3, though acute symptoms may improve within days to weeks of dose reduction or discontinuation 8, 5.